Business Context and Reporting Period
GE HealthCare Technologies Inc. filed this Form 8-K under Item 5.02 to disclose annual 2023 equity awards approved by the Talent, Culture, and Compensation Committee on March 1, 2023. The report was signed and filed on March 3, 2023.
The awards were granted under the Company’s 2023 Long-Term Incentive Plan to executive officers and other leaders, including the CEO and named executive officers.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial performance metrics.
Material Changes Versus the Prior Comparable Period
The filing does not present a prior-period comparison. It reports the structure and size of 2023 equity awards.
| Executive | RSUs | Options | PSUs |
|---|---|---|---|
| Peter J. Arduini, CEO | 39,425 | 109,994 | 70,683 |
| Helmut Zodl | 9,960 | 27,788 | 17,856 |
| Jan Makela | 9,130 | 25,472 | 16,368 |
Compensation Terms, Outlook, and Contingencies
- PSUs are linked to preset financial goals and may be adjusted based on total shareholder return relative to a peer group. They vest after a three-year performance period, subject to continued employment, and may vest at 0% to 200% of target.
- RSUs and options generally vest in three installments: 33% at 18 months, 33% at 30 months, and 34% at 42 months after the March 1, 2023 grant date.
- Unvested awards generally are forfeited upon termination, subject to limited exceptions for death, disability, retirement, or transfer to a successor employer.
- Vested options generally remain exercisable until the earlier of 90 days after termination or the option expiration date. Different treatment applies for death or disability, and vested options are forfeited upon termination for cause.
- The awards were based on the Company’s closing stock price on the grant date. The filing provides no financial guidance or management outlook.
Most Important Facts to Verify
- Confirm the complete terms, valuation, and expiration provisions in Exhibits 10.1 through 10.4.
- Verify the PSU financial targets, performance-period definitions, and total shareholder return adjustment methodology.
- Assess the potential future dilution and compensation expense associated with the RSUs, options, and PSUs.
- Confirm vesting and forfeiture treatment under the applicable employment and award agreements.